Compare BTU & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | VERA |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | 5400 | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2001 | 2021 |
| Metric | BTU | VERA |
|---|---|---|
| Price | $22.30 | $38.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $32.83 | ★ $81.30 |
| AVG Volume (30 Days) | 2.5M | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,861,500,000.00 | N/A |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $5.47 | $472.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.25 | $19.07 |
| 52 Week High | $41.14 | $56.05 |
| Indicator | BTU | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 46.21 |
| Support Level | $21.96 | $37.34 |
| Resistance Level | $31.39 | $38.59 |
| Average True Range (ATR) | 0.97 | 2.81 |
| MACD | 0.08 | -0.45 |
| Stochastic Oscillator | 17.12 | 21.33 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.